Algoma Central Corporation Announces Results of 2026 Annual General Meeting of Shareholders May 8, 2026 Algoma Central Corporation (TSX:ALC), held its Annual General Meeting of Shareholders (the “Meeting”) on May 7, 2026. Each of the matters set out below were voted upon at the Meeting and are described in greater detail in the Company’s Management Information Circular dated March 6, 2026, available online at www.algonet.com/investor-relations and www.sedarplus.ca. 1. Election of [...]
Patrick Cox: Tax the rich, bring back the guillotine! May 8, 2026 Iconic 90s shoe designer Patrick Cox, and soon-to-be Cordwainer, takes us on a trip down memory lane in this week's Square Mile and Me.
Telekom Srbija Secures U.S. EXIM Financing to Accelerate 5G Rollout May 8, 2026 Approval from the Export-Import Bank of the United States will support Serbia’s next-generation telecoms expansion and strengthen U.S.–Serbia technology and economic ties
Governments can’t ‘tax for growth’ – they need to get out of the way May 8, 2026 You cannot tax your way to growth and prosperity, and Labour’s track record suggests any extra revenue would go toward expanding benefits rather than productive investment, says Anne Strickland Amid the local elections, some MPs think they’ve cracked the code to win back voters – by raising taxes. Jeevun Sandher MP, parliamentary aide to the [...]
Esentia Announces Successful Pricing of 6.125% Senior Notes Due 2033 and 6.500% Senior Notes Due 2038 May 8, 2026 Esentia Energy Development, S.A.B. de C.V. (“ESENTIA” or the “Company”), today announced the pricing of U.S.$1,000,000,000.00 aggregate principal amount of its 6.125% Senior Notes due 2033 (the “2033 Notes”) and U.S$1,000,000,000.00 aggregate principal amount of its 6.500% Senior Notes due 2038 (the “2038 Notes” and, together with the 2033 Notes, the “Notes”) to be issued [...]
City calls on tech firms to tackle Britain’s fraud epidemic May 8, 2026 The City of London Corporation is calling on tech firms to help build a new digital identity verification network, designed to crack down on fraud and reduce the growing costs of financial scams. Under the plans, shared with City AM, consumers would verify their identity once with a trusted provider before reusing those credentials across [...]
Prothena Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026 Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate
NEAM Limited Hires Giri Singh May 7, 2026 New England Asset Management Limited (NEAM Limited) announces that Giri Singh has joined NEAM Limited’s London Branch as Head of Business Development, Europe. He will be responsible for expanding the firm’s UK and European insurance asset management business. Graham Kirk, Managing Director, NEAM Limited commented, “We’re very excited to bring someone of Giri’s experience and [...]
Algoma Central Corporation Reports Financial Results for the 2026 First Quarter May 7, 2026 Focused fleet growth, strategic opportunities, and built-in adaptability across domestic and international operations drove a resilient first quarter
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results May 7, 2026 Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026